{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058003","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.210265+00:00","generated_at":"2026-06-02T17:15:36.140012+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocular Therapeutix Q1 net loss $64.8M ($0.49/sh); revenue $14.8M up 10.4% YoY","bullets":["Net loss of $64.8M ($0.49/sh) vs $30.3M loss ($0.39/sh) in Q1 2023; includes $28M non-cash loss on debt extinguishment.","Total net revenue $14.8M, up 10.4% YoY, driven by DEXTENZA product sales.","Cash and equivalents $482.9M; Feb 2024 private placement raised $325M; cash runway expected into 2028.","Phase 3 SOL-1 wet AMD trial randomization started April 2024; site activation progressing under FDA SPA.","Pravin Dugel appointed Exec Chairman, President & CEO; Investor Day set for June 13, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058003","json":"https://secwatch.observer/filing/0001104659-24-058003.json","markdown":"https://secwatch.observer/filing/0001104659-24-058003.md","text":"https://secwatch.observer/filing/0001104659-24-058003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/0001104659-24-058003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/tm2413661d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T17:15:36.140012+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ced2b21593e29eae26df63cb644c0ca2ee72ab3d","claim":"OCULAR THERAPEUTIX, INC reported first quarter ended March 31, 2024 results: revenue $14.8 million, net income $(64.8) million, EPS $(0.49) per share.","evidence_excerpt":"Company believes that its current cash balance is sufficient to support its planned expenses, obligations, and capital expenditure requirements into 2028. Total net revenue was $14.8 million for the first quarter of 2024, a 10.4% increase over total net revenue of $13.4 million in the comparable period in 2023, driven by increased DEXTENZA sales. Total net revenue","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465924058003/0001104659-24-058003-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$14.8 million"},{"label":"Net income","value":"$(64.8) million"},{"label":"EPS","value":"$(0.49) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}